MedTrace Logo

PS-Omega3 Supplementation to Attention Deficit Hyperactivity Disorder (ADHD) Children

NCT00700323 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2008-06-18

No results posted yet for this study

Summary

To assess the effect of phosphatidylserine-omega-3 consumption on the immune system parameters in children suffering from attention and concentration deficits.

Conditions

  • ADHD

Interventions

DIETARY_SUPPLEMENT

PS-Omega3 conjugate supplementation

DIETARY_SUPPLEMENT

placebo

Sponsors & Collaborators

  • Enzymotec

    collaborator INDUSTRY

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Nachum Vaisman, Prof' · Tel-Aviv Sourasky Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00700323 on ClinicalTrials.gov